Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.49 |
| ▸ | FEN1 | P39748 | 1/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16501994 | 0.78 | ROCK2 (0.47) | ROCK2ROCK1ERN1 | |
| SCHEMBL18002061 | 0.77 | ALOX5AP (0.50) | ALOX5APFEN1ERN1 | |
| SCHEMBL26635214 | 0.77 | FEN1 (0.54) | ALOX5APFEN1NPBWR1 | |
| SCHEMBL30540254 | 0.77 | FEN1 (0.54) | ALOX5APFEN1NPBWR1 | |
| SCHEMBL27653523 | 0.75 | ALOX5AP (0.49) | ALOX5APFEN1NPBWR1 | |
| SCHEMBL1956753 | 0.73 | AKT2 (0.50) | FEN1ROCK2ROCK1ERN1 | |
| SCHEMBL28199128 | 0.73 | ROCK2 (0.44) | ALOX5APFEN1NPBWR1ROCK2ROCK1 | |
| SCHEMBL18002259 | 0.73 | ALOX5AP (0.50) | ALOX5APFEN1ERN1 | |
| SCHEMBL18002200 | 0.72 | PTGDR2 (0.51) | ALOX5APFEN1ERN1 | |
| SCHEMBL3401500 | 0.72 | ROCK2 (0.45) | ALOX5APFEN1NPBWR1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2010037059-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010037059-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | ALOX5AP 53/4885FEN1 3869/4885NPBWR1 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.